Development and Validation of a stability indicating RP-HPLC method for simultaneous determination of Telmisartan, Chlorthalidone and Cilnidipine in pharmaceutical combined dosage forms

Mathews Bommella*, Ramisetti Nageswara Rao, Priyanka Peddi, Mukkanti Khagga, Sarbani pal

The study describes development and subsequent validation of a stability indicating reverse-phase HPLC method for simultaneous estimation of the Telmisartan, Chlorthalidone and Cilnidipine in combined solid dosage forms using RP-HPLC. Separation was accomplished on Kromasil 250 x 4.6 mm, 5mm C₁₈ column using 0.1% OPA buffer and acetonitrile (57:43 v/v) as mobile phase pumped through at a flow rate of 1.2 ml/min at 30°C. Optimized wavelength was 238nm. Retention time of Telmisartan, Chlorthalidone and Cilnidipine were found to be 3.106min, 2.573min and 3.924 min respectively. %RSD of the Telmisartan, Chlorthalidone and Cilnidipine were found to be 0.87, 0.96 and 0.94 respectively. % recovery was obtained as 100.18%, 100.06% and 100.13% for Telmisartan, Chlorthalidone and Cilnidipine respectively. The proposed method also proved to be suitable as a rapid and reliable quality control method.